Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

In a trial comparing enfortumab vedotin and a PD-1 inhibitor with chemotherapy in patients with untreated advanced or metastatic urothelial cancer, progression-free and overall survival nearly doubled with the experimental treatment.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 390; no. 10; pp. 875 - 888
Main Authors Powles, Thomas, Valderrama, Begoña P., Gupta, Shilpa, Bedke, Jens, Kikuchi, Eiji, Hoffman-Censits, Jean, Iyer, Gopa, Vulsteke, Christof, Park, Se Hoon, Shin, Sang Joon, Castellano, Daniel, Fornarini, Giuseppe, Li, Jian-Ri, Gümüş, Mahmut, Mar, Nataliya, Loriot, Yohann, Fléchon, Aude, Duran, Ignacio, Drakaki, Alexandra, Narayanan, Sujata, Yu, Xuesong, Gorla, Seema, Homet Moreno, Blanca, van der Heijden, Michiel S.
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 07.03.2024
Subjects
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Bladder cancer
Body weight
Cancer
Carboplatin
Carboplatin - administration & dosage
Carboplatin - adverse effects
Carboplatin - therapeutic use
Carcinoma, Transitional Cell - drug therapy
Carcinoma, Transitional Cell - pathology
Carcinoma, Transitional Cell - secondary
Chemotherapy
Cisplatin
Cisplatin - administration & dosage
Cisplatin - adverse effects
Cisplatin - therapeutic use
Clinical outcomes
Drug dosages
Gemcitabine
Gemcitabine - administration & dosage
Gemcitabine - adverse effects
Gemcitabine - therapeutic use
Genitourinary Cancer
Hematology
Humans
Immunotherapy
Metastases
Metastasis
Monoclonal antibodies
Oncology
Patients
Pembrolizumab
Platinum
Prostate Disease
Prostate Disease General
Safety
Survival
Survival Analysis
Targeted cancer therapy
Treatments in Oncology
Urinary Bladder Neoplasms
Urologic Neoplasms - drug therapy
Urologic Neoplasms - pathology
Urologic Neoplasms - secondary
Urology
Urothelial cancer
Urothelial carcinoma
United States > US
Online AccessGet full text

Cover

Abstract In a trial comparing enfortumab vedotin and a PD-1 inhibitor with chemotherapy in patients with untreated advanced or metastatic urothelial cancer, progression-free and overall survival nearly doubled with the experimental treatment.
AbstractList In a trial comparing enfortumab vedotin and a PD-1 inhibitor with chemotherapy in patients with untreated advanced or metastatic urothelial cancer, progression-free and overall survival nearly doubled with the experimental treatment.
AbstractBackgroundNo treatment has surpassed platinum-based chemotherapy in improving overall survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma.MethodsWe conducted a phase 3, global, open-label, randomized trial to compare the efficacy and safety of enfortumab vedotin and pembrolizumab with the efficacy and safety of platinum-based chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma. Patients were randomly assigned in a 1:1 ratio to receive 3-week cycles of enfortumab vedotin (at a dose of 1.25 mg per kilogram of body weight intravenously on days 1 and 8) and pembrolizumab (at a dose of 200 mg intravenously on day 1) (enfortumab vedotin–pembrolizumab group) or gemcitabine and either cisplatin or carboplatin (determined on the basis of eligibility to receive cisplatin) (chemotherapy group). The primary end points were progression-free survival as assessed by blinded independent central review and overall survival.ResultsA total of 886 patients underwent randomization: 442 to the enfortumab vedotin–pembrolizumab group and 444 to the chemotherapy group. As of August 8, 2023, the median duration of follow-up for survival was 17.2 months. Progression-free survival was longer in the enfortumab vedotin–pembrolizumab group than in the chemotherapy group (median, 12.5 months vs. 6.3 months; hazard ratio for disease progression or death, 0.45; 95% confidence interval [CI], 0.38 to 0.54; P<0.001), as was overall survival (median, 31.5 months vs. 16.1 months; hazard ratio for death, 0.47; 95% CI, 0.38 to 0.58; P<0.001). The median number of cycles was 12 (range, 1 to 46) in the enfortumab vedotin–pembrolizumab group and 6 (range, 1 to 6) in the chemotherapy group. Treatment-related adverse events of grade 3 or higher occurred in 55.9% of the patients in the enfortumab vedotin–pembrolizumab group and in 69.5% of those in the chemotherapy group.ConclusionsTreatment with enfortumab vedotin and pembrolizumab resulted in significantly better outcomes than chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma, with a safety profile consistent with that in previous reports. (Funded by Astellas Pharma US and others; EV-302 ClinicalTrials.gov number, NCT04223856.)
No treatment has surpassed platinum-based chemotherapy in improving overall survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma. We conducted a phase 3, global, open-label, randomized trial to compare the efficacy and safety of enfortumab vedotin and pembrolizumab with the efficacy and safety of platinum-based chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma. Patients were randomly assigned in a 1:1 ratio to receive 3-week cycles of enfortumab vedotin (at a dose of 1.25 mg per kilogram of body weight intravenously on days 1 and 8) and pembrolizumab (at a dose of 200 mg intravenously on day 1) (enfortumab vedotin-pembrolizumab group) or gemcitabine and either cisplatin or carboplatin (determined on the basis of eligibility to receive cisplatin) (chemotherapy group). The primary end points were progression-free survival as assessed by blinded independent central review and overall survival. A total of 886 patients underwent randomization: 442 to the enfortumab vedotin-pembrolizumab group and 444 to the chemotherapy group. As of August 8, 2023, the median duration of follow-up for survival was 17.2 months. Progression-free survival was longer in the enfortumab vedotin-pembrolizumab group than in the chemotherapy group (median, 12.5 months vs. 6.3 months; hazard ratio for disease progression or death, 0.45; 95% confidence interval [CI], 0.38 to 0.54; P<0.001), as was overall survival (median, 31.5 months vs. 16.1 months; hazard ratio for death, 0.47; 95% CI, 0.38 to 0.58; P<0.001). The median number of cycles was 12 (range, 1 to 46) in the enfortumab vedotin-pembrolizumab group and 6 (range, 1 to 6) in the chemotherapy group. Treatment-related adverse events of grade 3 or higher occurred in 55.9% of the patients in the enfortumab vedotin-pembrolizumab group and in 69.5% of those in the chemotherapy group. Treatment with enfortumab vedotin and pembrolizumab resulted in significantly better outcomes than chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma, with a safety profile consistent with that in previous reports. (Funded by Astellas Pharma US and others; EV-302 ClinicalTrials.gov number, NCT04223856.).
No treatment has surpassed platinum-based chemotherapy in improving overall survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma.BACKGROUNDNo treatment has surpassed platinum-based chemotherapy in improving overall survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma.We conducted a phase 3, global, open-label, randomized trial to compare the efficacy and safety of enfortumab vedotin and pembrolizumab with the efficacy and safety of platinum-based chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma. Patients were randomly assigned in a 1:1 ratio to receive 3-week cycles of enfortumab vedotin (at a dose of 1.25 mg per kilogram of body weight intravenously on days 1 and 8) and pembrolizumab (at a dose of 200 mg intravenously on day 1) (enfortumab vedotin-pembrolizumab group) or gemcitabine and either cisplatin or carboplatin (determined on the basis of eligibility to receive cisplatin) (chemotherapy group). The primary end points were progression-free survival as assessed by blinded independent central review and overall survival.METHODSWe conducted a phase 3, global, open-label, randomized trial to compare the efficacy and safety of enfortumab vedotin and pembrolizumab with the efficacy and safety of platinum-based chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma. Patients were randomly assigned in a 1:1 ratio to receive 3-week cycles of enfortumab vedotin (at a dose of 1.25 mg per kilogram of body weight intravenously on days 1 and 8) and pembrolizumab (at a dose of 200 mg intravenously on day 1) (enfortumab vedotin-pembrolizumab group) or gemcitabine and either cisplatin or carboplatin (determined on the basis of eligibility to receive cisplatin) (chemotherapy group). The primary end points were progression-free survival as assessed by blinded independent central review and overall survival.A total of 886 patients underwent randomization: 442 to the enfortumab vedotin-pembrolizumab group and 444 to the chemotherapy group. As of August 8, 2023, the median duration of follow-up for survival was 17.2 months. Progression-free survival was longer in the enfortumab vedotin-pembrolizumab group than in the chemotherapy group (median, 12.5 months vs. 6.3 months; hazard ratio for disease progression or death, 0.45; 95% confidence interval [CI], 0.38 to 0.54; P<0.001), as was overall survival (median, 31.5 months vs. 16.1 months; hazard ratio for death, 0.47; 95% CI, 0.38 to 0.58; P<0.001). The median number of cycles was 12 (range, 1 to 46) in the enfortumab vedotin-pembrolizumab group and 6 (range, 1 to 6) in the chemotherapy group. Treatment-related adverse events of grade 3 or higher occurred in 55.9% of the patients in the enfortumab vedotin-pembrolizumab group and in 69.5% of those in the chemotherapy group.RESULTSA total of 886 patients underwent randomization: 442 to the enfortumab vedotin-pembrolizumab group and 444 to the chemotherapy group. As of August 8, 2023, the median duration of follow-up for survival was 17.2 months. Progression-free survival was longer in the enfortumab vedotin-pembrolizumab group than in the chemotherapy group (median, 12.5 months vs. 6.3 months; hazard ratio for disease progression or death, 0.45; 95% confidence interval [CI], 0.38 to 0.54; P<0.001), as was overall survival (median, 31.5 months vs. 16.1 months; hazard ratio for death, 0.47; 95% CI, 0.38 to 0.58; P<0.001). The median number of cycles was 12 (range, 1 to 46) in the enfortumab vedotin-pembrolizumab group and 6 (range, 1 to 6) in the chemotherapy group. Treatment-related adverse events of grade 3 or higher occurred in 55.9% of the patients in the enfortumab vedotin-pembrolizumab group and in 69.5% of those in the chemotherapy group.Treatment with enfortumab vedotin and pembrolizumab resulted in significantly better outcomes than chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma, with a safety profile consistent with that in previous reports. (Funded by Astellas Pharma US and others; EV-302 ClinicalTrials.gov number, NCT04223856.).CONCLUSIONSTreatment with enfortumab vedotin and pembrolizumab resulted in significantly better outcomes than chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma, with a safety profile consistent with that in previous reports. (Funded by Astellas Pharma US and others; EV-302 ClinicalTrials.gov number, NCT04223856.).
Author van der Heijden, Michiel S.
Yu, Xuesong
Valderrama, Begoña P.
Mar, Nataliya
Castellano, Daniel
Drakaki, Alexandra
Narayanan, Sujata
Fornarini, Giuseppe
Iyer, Gopa
Shin, Sang Joon
Kikuchi, Eiji
Vulsteke, Christof
Park, Se Hoon
Loriot, Yohann
Hoffman-Censits, Jean
Gorla, Seema
Bedke, Jens
Li, Jian-Ri
Fléchon, Aude
Homet Moreno, Blanca
Gümüş, Mahmut
Duran, Ignacio
Powles, Thomas
Gupta, Shilpa
Author_xml – sequence: 1
  givenname: Thomas
  surname: Powles
  fullname: Powles, Thomas
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 2
  givenname: Begoña P.
  surname: Valderrama
  fullname: Valderrama, Begoña P.
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 3
  givenname: Shilpa
  surname: Gupta
  fullname: Gupta, Shilpa
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 4
  givenname: Jens
  surname: Bedke
  fullname: Bedke, Jens
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 5
  givenname: Eiji
  surname: Kikuchi
  fullname: Kikuchi, Eiji
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 6
  givenname: Jean
  surname: Hoffman-Censits
  fullname: Hoffman-Censits, Jean
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 7
  givenname: Gopa
  surname: Iyer
  fullname: Iyer, Gopa
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 8
  givenname: Christof
  orcidid: 0000-0002-4607-5660
  surname: Vulsteke
  fullname: Vulsteke, Christof
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 9
  givenname: Se Hoon
  surname: Park
  fullname: Park, Se Hoon
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 10
  givenname: Sang Joon
  surname: Shin
  fullname: Shin, Sang Joon
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 11
  givenname: Daniel
  surname: Castellano
  fullname: Castellano, Daniel
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 12
  givenname: Giuseppe
  surname: Fornarini
  fullname: Fornarini, Giuseppe
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 13
  givenname: Jian-Ri
  surname: Li
  fullname: Li, Jian-Ri
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 14
  givenname: Mahmut
  surname: Gümüş
  fullname: Gümüş, Mahmut
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 15
  givenname: Nataliya
  surname: Mar
  fullname: Mar, Nataliya
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 16
  givenname: Yohann
  surname: Loriot
  fullname: Loriot, Yohann
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 17
  givenname: Aude
  surname: Fléchon
  fullname: Fléchon, Aude
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 18
  givenname: Ignacio
  surname: Duran
  fullname: Duran, Ignacio
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 19
  givenname: Alexandra
  surname: Drakaki
  fullname: Drakaki, Alexandra
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 20
  givenname: Sujata
  surname: Narayanan
  fullname: Narayanan, Sujata
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 21
  givenname: Xuesong
  surname: Yu
  fullname: Yu, Xuesong
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 22
  givenname: Seema
  surname: Gorla
  fullname: Gorla, Seema
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 23
  givenname: Blanca
  surname: Homet Moreno
  fullname: Homet Moreno, Blanca
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
– sequence: 24
  givenname: Michiel S.
  surname: van der Heijden
  fullname: van der Heijden, Michiel S.
  organization: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) — all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp — both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) — both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris–Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.)
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38446675$$D View this record in MEDLINE/PubMed
BookMark eNp10UtLxDAQAOAgiq6Po1cpiOClmlfT5ijL-mJ9HFyvYdqk2KVNNEkF_fVGVw8K5pIw880QZrbRunXWILRP8AnBhTi9nV3fOKCMUELKNTQhBWM551isownGtMp5KdkW2g5hidMhXG6iLVZxLkRZTNB8Zlvn4zhAnT0a7WJnM7A6uzdD7V3fvX9lUnBhozcQjc7O9CvYJj0W3sUn03fQZ9PPiN9FGy30wex93ztocT57mF7m87uLq-nZPG9YQWIOBIOAVmpW1rKpKAUDrcZSMFG3mGnNa8qZSSmmUwJaIihra6mJ4RQLyXbQ8arvs3cvowlRDV1oTN-DNW4MikpOSVWWBCd6-Icu3eht-l1SrCqIJLJK6uBbjfVgtHr23QD-Tf3MKQG2Ao13IXjTqqaLEDuXpgJdrwhWn9tQv7aRqvI_VT-N__NHKz8MQVmzHP5xHwbXleM
CitedBy_id crossref_primary_10_1007_s15004_024_0545_x
crossref_primary_10_3390_cancers16132420
crossref_primary_10_3389_fphar_2025_1525733
crossref_primary_10_1200_JCO_23_02233
crossref_primary_10_3390_curroncol31110511
crossref_primary_10_3390_ijms25179696
crossref_primary_10_1016_j_eururo_2024_03_029
crossref_primary_10_1007_s10585_024_10296_0
crossref_primary_10_1016_j_eururo_2024_03_032
crossref_primary_10_1136_jitc_2024_010572
crossref_primary_10_1001_jamanetworkopen_2025_0250
crossref_primary_10_1007_s40271_024_00709_3
crossref_primary_10_3389_fimmu_2024_1432586
crossref_primary_10_1007_s15015_024_4079_8
crossref_primary_10_1158_2159_8290_CD_24_0708
crossref_primary_10_1158_1535_7163_MCT_24_0267
crossref_primary_10_58931_cot_2024_1329
crossref_primary_10_1016_j_jdcr_2024_12_019
crossref_primary_10_1038_s41598_024_79334_x
crossref_primary_10_1038_s41571_024_00890_2
crossref_primary_10_3390_cancers16183201
crossref_primary_10_1016_j_lfs_2024_122910
crossref_primary_10_3390_cancers17020251
crossref_primary_10_1148_radiol_233459
crossref_primary_10_1007_s00262_024_03839_7
crossref_primary_10_1016_j_esmorw_2024_100110
crossref_primary_10_3390_cancers16244127
crossref_primary_10_3390_cimb47010043
crossref_primary_10_3390_ijms252212126
crossref_primary_10_3390_cancers16081536
crossref_primary_10_1016_j_molstruc_2024_140156
crossref_primary_10_3346_jkms_2024_39_e320
crossref_primary_10_1016_j_eururo_2024_11_026
crossref_primary_10_1055_a_2442_4797
crossref_primary_10_1210_jcemcr_luae212
crossref_primary_10_3390_cancers16173071
crossref_primary_10_1007_s00761_024_01626_8
crossref_primary_10_1016_j_clgc_2024_102212
crossref_primary_10_3390_cells13211803
crossref_primary_10_1016_j_euf_2024_04_001
crossref_primary_10_1001_jamaoncol_2024_3900
crossref_primary_10_3389_fonc_2024_1468784
crossref_primary_10_1016_j_euf_2024_04_005
crossref_primary_10_3390_ijms25168899
crossref_primary_10_1016_j_clgc_2024_102203
crossref_primary_10_1016_j_jdcr_2024_12_037
crossref_primary_10_3390_curroncol32040187
crossref_primary_10_1016_j_euf_2024_05_018
crossref_primary_10_3389_fimmu_2024_1464092
crossref_primary_10_1016_j_eururo_2024_11_012
crossref_primary_10_3390_cancers17020232
crossref_primary_10_1111_cup_14689
crossref_primary_10_1016_j_medj_2024_11_004
crossref_primary_10_3390_cancers16193345
crossref_primary_10_1080_14712598_2024_2408756
crossref_primary_10_1111_iju_70040
crossref_primary_10_1186_s40164_024_00579_3
crossref_primary_10_1097_MOU_0000000000001237
crossref_primary_10_1038_s41467_024_55331_6
crossref_primary_10_1097_MOU_0000000000001238
crossref_primary_10_1111_iju_15528
crossref_primary_10_1016_j_urolonc_2024_09_030
crossref_primary_10_1177_17562872241249073
crossref_primary_10_1097_MOU_0000000000001230
crossref_primary_10_1016_j_eururo_2024_11_001
crossref_primary_10_1002_mco2_671
crossref_primary_10_1016_j_breast_2024_103838
crossref_primary_10_1016_j_euo_2024_05_012
crossref_primary_10_1080_14737140_2025_2473645
crossref_primary_10_3390_cancers17050898
crossref_primary_10_1007_s11523_024_01119_z
crossref_primary_10_1016_j_urolonc_2025_03_001
crossref_primary_10_1001_jamanetworkopen_2024_9426
crossref_primary_10_1016_j_jaad_2024_08_036
crossref_primary_10_3390_cancers16173056
crossref_primary_10_3390_ijms25126325
crossref_primary_10_1016_j_urology_2025_03_034
crossref_primary_10_1172_jci_insight_186062
crossref_primary_10_3390_cancers16193330
crossref_primary_10_7759_cureus_77948
crossref_primary_10_1056_NEJMe2411608
crossref_primary_10_1097_CCO_0000000000001064
crossref_primary_10_48095_cccu2025008
crossref_primary_10_1016_j_clgc_2024_102228
crossref_primary_10_1016_j_urolonc_2024_09_020
crossref_primary_10_4103_iju_iju_105_24
crossref_primary_10_1007_s00262_024_03871_7
crossref_primary_10_1007_s13691_025_00749_y
crossref_primary_10_1007_s00120_024_02442_z
crossref_primary_10_1148_rg_240056
crossref_primary_10_1111_iju_70029
crossref_primary_10_1016_j_clgc_2024_102243
crossref_primary_10_1056_NEJMoa2401726
crossref_primary_10_1007_s40265_024_02111_7
crossref_primary_10_1007_s12094_024_03651_w
crossref_primary_10_4103_iju_iju_62_24
crossref_primary_10_1007_s00120_024_02487_0
crossref_primary_10_1038_s41585_024_00951_2
crossref_primary_10_1093_oncolo_oyae215
crossref_primary_10_1007_s12325_024_02922_w
crossref_primary_10_1016_j_esmoop_2025_104506
crossref_primary_10_3390_jcm13247498
crossref_primary_10_1002_2056_4538_70017
crossref_primary_10_1200_PO_24_00766
crossref_primary_10_1016_j_eururo_2024_06_022
crossref_primary_10_3389_fonc_2024_1493854
crossref_primary_10_3390_ph17111547
crossref_primary_10_1016_j_clgc_2024_102236
crossref_primary_10_1016_j_euo_2024_09_014
crossref_primary_10_1007_s00261_024_04767_x
crossref_primary_10_1007_s00280_025_04764_x
crossref_primary_10_1016_j_clgc_2024_102238
crossref_primary_10_1016_j_euo_2024_09_018
crossref_primary_10_1186_s12894_024_01674_7
crossref_primary_10_3389_fphar_2024_1412292
crossref_primary_10_1016_j_path_2024_09_003
crossref_primary_10_1016_j_urolonc_2024_12_267
crossref_primary_10_3390_cancers16132400
crossref_primary_10_1016_j_clgc_2025_102335
crossref_primary_10_1002_pros_24846
crossref_primary_10_1016_j_euo_2024_10_003
crossref_primary_10_1007_s10147_025_02729_x
crossref_primary_10_1016_j_euros_2024_09_011
crossref_primary_10_3390_medicina60122103
crossref_primary_10_1200_JCO_25_00179
crossref_primary_10_1007_s11764_024_01698_w
crossref_primary_10_1080_14737140_2024_2405104
crossref_primary_10_1080_21645515_2024_2440165
crossref_primary_10_3390_curroncol31080352
crossref_primary_10_1016_j_urolonc_2024_11_010
crossref_primary_10_1007_s00092_024_6415_x
crossref_primary_10_1016_j_clgc_2024_102248
crossref_primary_10_3390_cancers16234100
crossref_primary_10_1016_j_clgc_2025_102326
crossref_primary_10_1177_23523735241296763
crossref_primary_10_1002_cncr_35421
crossref_primary_10_1016_j_clgc_2024_102261
crossref_primary_10_1002_bco2_488
crossref_primary_10_1016_S1470_2045_24_00212_2
crossref_primary_10_1158_1078_0432_CCR_23_3518
crossref_primary_10_1007_s11934_024_01245_1
crossref_primary_10_1007_s00120_024_02440_1
crossref_primary_10_1016_j_eururo_2024_12_002
crossref_primary_10_1080_1120009X_2024_2388475
crossref_primary_10_1016_j_annonc_2024_12_002
crossref_primary_10_1016_j_urolonc_2024_05_015
crossref_primary_10_1158_2767_9764_CRC_23_0493
crossref_primary_10_1080_21645515_2024_2379086
crossref_primary_10_1016_j_clgc_2024_102273
crossref_primary_10_1016_j_clgc_2024_102154
crossref_primary_10_1016_j_clgc_2025_102312
crossref_primary_10_1158_1078_0432_CCR_23_3924
crossref_primary_10_1080_1750743X_2025_2483152
crossref_primary_10_3390_ijms251910348
crossref_primary_10_1093_oncolo_oyae302
crossref_primary_10_1111_bju_16662
crossref_primary_10_1016_j_clgc_2024_102270
crossref_primary_10_1016_j_medj_2024_04_006
crossref_primary_10_36290_xon_2024_044
crossref_primary_10_1097_CCO_0000000000001141
crossref_primary_10_1016_j_esmoop_2024_103985
crossref_primary_10_36290_xon_2024_047
crossref_primary_10_3389_fonc_2024_1493922
crossref_primary_10_1038_s44276_024_00104_3
crossref_primary_10_1177_17588359241305091
crossref_primary_10_2340_sju_v60_43236
crossref_primary_10_1016_j_clgc_2024_102284
crossref_primary_10_1016_j_euf_2024_06_003
crossref_primary_10_1016_j_clgc_2024_102288
crossref_primary_10_1016_j_clgc_2025_102301
crossref_primary_10_1177_11795549251321147
crossref_primary_10_3389_fonc_2024_1434814
crossref_primary_10_1007_s11934_024_01242_4
crossref_primary_10_1016_j_cger_2025_01_003
crossref_primary_10_1016_j_eururo_2024_08_012
crossref_primary_10_3390_molecules29235618
crossref_primary_10_1016_j_fjurol_2024_102704
crossref_primary_10_1007_s00761_024_01547_6
crossref_primary_10_1136_bmjonc_2024_000368
crossref_primary_10_3390_curroncol31090420
crossref_primary_10_1016_j_jdcr_2024_10_019
crossref_primary_10_1055_a_2444_3096
crossref_primary_10_1007_s11523_024_01074_9
crossref_primary_10_3389_fonc_2025_1532421
crossref_primary_10_1200_GO_24_00431
crossref_primary_10_1177_23523735241289237
crossref_primary_10_1016_j_clgc_2024_102176
crossref_primary_10_1007_s00432_025_06131_y
crossref_primary_10_1016_j_acuro_2025_501719
crossref_primary_10_1055_a_2311_8013
crossref_primary_10_1016_j_esmoop_2024_103725
crossref_primary_10_3390_ijms25094945
crossref_primary_10_1007_s13629_025_00467_3
crossref_primary_10_1136_ijgc_2024_005607
crossref_primary_10_3389_fphar_2024_1377924
crossref_primary_10_1007_s11654_024_00611_2
crossref_primary_10_1056_NEJMoa2408154
crossref_primary_10_1016_j_ijbiomac_2025_140767
crossref_primary_10_1177_23523735251317865
crossref_primary_10_1186_s12967_024_06003_y
crossref_primary_10_1016_j_esmorw_2024_100094
crossref_primary_10_1177_17588359241305088
crossref_primary_10_3389_fonc_2024_1453338
crossref_primary_10_1016_j_eururo_2024_05_001
crossref_primary_10_1111_iju_15492
crossref_primary_10_3390_cells13211779
crossref_primary_10_1097_CCO_0000000000001129
crossref_primary_10_3390_siuj6010020
crossref_primary_10_1007_s10147_024_02526_y
crossref_primary_10_1056_NEJMe2400311
crossref_primary_10_3390_cancers16122246
crossref_primary_10_1016_j_esmoop_2024_103972
crossref_primary_10_1016_j_fjurol_2024_102722
crossref_primary_10_3389_fimmu_2024_1487227
crossref_primary_10_3390_cancers17030433
crossref_primary_10_1016_j_opresp_2024_100349
crossref_primary_10_1177_17588359241295544
crossref_primary_10_2147_CMAR_S445529
crossref_primary_10_1016_j_ctrv_2024_102847
crossref_primary_10_1200_JCO_24_01675
crossref_primary_10_1016_j_clgc_2024_102198
crossref_primary_10_1016_j_eururo_2025_02_023
crossref_primary_10_1038_s41571_024_00884_0
crossref_primary_10_1111_iju_15640
crossref_primary_10_3389_fonc_2024_1326715
crossref_primary_10_1016_j_jfma_2024_10_006
crossref_primary_10_1080_13543784_2025_2473695
crossref_primary_10_1002_path_6335
crossref_primary_10_1186_s42047_024_00158_0
crossref_primary_10_1016_j_currproblcancer_2024_101149
crossref_primary_10_1177_23247096241257333
crossref_primary_10_1080_21645515_2024_2414542
crossref_primary_10_18632_oncoscience_596
crossref_primary_10_1002_cncr_35601
crossref_primary_10_1016_j_acuroe_2025_501719
crossref_primary_10_1016_j_urolonc_2024_07_010
crossref_primary_10_1080_14728214_2024_2339906
crossref_primary_10_1016_j_annonc_2024_03_001
crossref_primary_10_1200_EDBK_438640
crossref_primary_10_1016_j_fjurol_2024_102741
crossref_primary_10_1016_j_clon_2024_05_013
crossref_primary_10_3390_cancers16152648
crossref_primary_10_1002_cam4_70368
crossref_primary_10_1007_s11523_024_01099_0
crossref_primary_10_1093_jjco_hyaf008
crossref_primary_10_1038_s41590_024_02015_4
crossref_primary_10_1158_1078_0432_CCR_24_1728
crossref_primary_10_3390_cancers17030509
crossref_primary_10_1111_bju_16529
crossref_primary_10_1016_j_bulcan_2024_12_001
crossref_primary_10_1016_j_ctrv_2025_102900
crossref_primary_10_1111_bju_16643
crossref_primary_10_1016_j_clgc_2024_102090
crossref_primary_10_1016_j_clgc_2024_102093
crossref_primary_10_1016_j_euo_2024_12_009
crossref_primary_10_1016_j_eururo_2025_01_002
crossref_primary_10_1007_s11255_024_04341_w
crossref_primary_10_1186_s12967_025_06237_4
crossref_primary_10_1002_mco2_765
crossref_primary_10_1016_j_fpurol_2024_07_206
crossref_primary_10_1097_MOU_0000000000001261
crossref_primary_10_1016_j_euf_2024_03_005
crossref_primary_10_1097_MOU_0000000000001263
crossref_primary_10_3389_fonc_2024_1430285
crossref_primary_10_1007_s00120_024_02421_4
crossref_primary_10_1016_j_esmogo_2025_100154
crossref_primary_10_1177_23523735251317423
crossref_primary_10_3390_mps7040058
crossref_primary_10_3390_cancers16112086
crossref_primary_10_3390_cancers16091780
crossref_primary_10_1016_j_annonc_2025_01_011
crossref_primary_10_1016_j_fpurol_2024_07_211
crossref_primary_10_3389_fphar_2025_1556245
crossref_primary_10_1016_j_euo_2024_12_006
crossref_primary_10_1016_j_eururo_2025_01_009
crossref_primary_10_1016_j_medj_2024_10_018
crossref_primary_10_1007_s10147_024_02644_7
crossref_primary_10_1016_j_medj_2025_100637
crossref_primary_10_1016_j_urolonc_2024_07_006
crossref_primary_10_3390_cancers16234078
crossref_primary_10_1016_j_urolonc_2024_07_004
crossref_primary_10_1016_j_jaad_2024_07_1463
Cites_doi 10.1016/S0140-6736(20)30230-0
10.1016/j.urolonc.2023.03.012
10.1200/JCO.2023.41.6_suppl.483
10.1056/NEJMoa2309863
10.1200/JCO.2023.41.6_suppl.466
10.1016/S1470-2045(20)30541-6
10.1016/S1470-2045(21)00094-2
10.1200/JCO.22.01643
10.1016/j.annonc.2021.11.012
10.1056/NEJMoa2002788
10.1056/NEJMoa2035807
10.2147/CLEP.S409791
10.1200/JCO.22.02887
10.1016/S1470-2045(21)00152-2
10.1200/JCO.2023.41.6_suppl.572
10.1200/JCO.2021.39.15_suppl.4508
10.1200/JCO.19.01140
ContentType Journal Article
Contributor Adorno Febles, Victor
van der Heijden, Michiel
Iyer, Gopa
Devitt, Michael
Domenech, Montserrat
Katolicka, Jana
Swami, Umang
Polee, Marco
Gupta, Shilpa
Nyirady, Peter
Buchler, Tomas
Mendez Vidal, Maria Jose
De Bock, Marlies
Galli, Luca
Alonso Gordoa, Teresa
Csoszi, Tibor
Tartas, Sophie
Castonguay, Vincent
Rodriguez Vida, Alejo
Miller, Alan
Sridhar, Srikala
Juan Fita, Maria Jose
Oezdemir, Berna
Jain, Rohit
Goodman, Jr, Oscar
Arkosy, Peter
de Wit, Ronald
Drakaki, Alexandra
Dumez, Herlinde
Vulsteke, Christof
Necchi, Andrea
Alimohamed, Nimira
Fornarini, Giuseppe
Petrylak, Daniel
Gallardo Diaz, Enrique
Perez Gracia, Jose
Molina Cerrillo, Javier
Nole, Franco
Eigl, Bernhard
Flechon, Aude
Perez Valderrama, Begona
Rose, April
Tripathi, Abhishek
Iacovelli, Roberto
Melichar, Bohuslav
Castellano Gauna, Daniel
Usrey, Marc
Arafat, Waddah
Font Pous, Alberto
Van Aelst, Filip
Puente Vazquez, Javier
Dawson, Nancy
Los, Maartje
Balar, Arjun
Kubica, Ronald
Sautois, Brieuc
Garrot, Louis
Navaid, Musharraf
Cheng, Susanna
Marquette, Carrie
Bansal, Pranshu
Pless, Miklos
Bu
Contributor_xml – sequence: 1
  givenname: Nancy
  surname: Dawson
  fullname: Dawson, Nancy
– sequence: 2
  givenname: Shilpa
  surname: Gupta
  fullname: Gupta, Shilpa
– sequence: 3
  givenname: Umang
  surname: Swami
  fullname: Swami, Umang
– sequence: 4
  givenname: Jean
  surname: Hoffman-Censits
  fullname: Hoffman-Censits, Jean
– sequence: 5
  givenname: Rohit
  surname: Jain
  fullname: Jain, Rohit
– sequence: 6
  givenname: Matthew
  surname: Galsky
  fullname: Galsky, Matthew
– sequence: 7
  givenname: Alexandra
  surname: Drakaki
  fullname: Drakaki, Alexandra
– sequence: 8
  givenname: Michael
  surname: Devitt
  fullname: Devitt, Michael
– sequence: 9
  givenname: Alan
  surname: Miller
  fullname: Miller, Alan
– sequence: 10
  givenname: Sudy
  surname: Jahangiri
  fullname: Jahangiri, Sudy
– sequence: 11
  givenname: Manojkumar
  surname: Bupathi
  fullname: Bupathi, Manojkumar
– sequence: 12
  givenname: Marc
  surname: Usrey
  fullname: Usrey, Marc
– sequence: 13
  givenname: Arielle
  surname: Lee
  fullname: Lee, Arielle
– sequence: 14
  givenname: Thomas
  surname: Flaig
  fullname: Flaig, Thomas
– sequence: 15
  givenname: Nataliya
  surname: Mar
  fullname: Mar, Nataliya
– sequence: 16
  givenname: Gopa
  surname: Iyer
  fullname: Iyer, Gopa
– sequence: 17
  givenname: Daniel
  surname: Petrylak
  fullname: Petrylak, Daniel
– sequence: 18
  givenname: Arjun
  surname: Balar
  fullname: Balar, Arjun
– sequence: 19
  givenname: Victor
  surname: Adorno Febles
  fullname: Adorno Febles, Victor
– sequence: 20
  givenname: Abhishek
  surname: Tripathi
  fullname: Tripathi, Abhishek
– sequence: 21
  givenname: Waddah
  surname: Arafat
  fullname: Arafat, Waddah
– sequence: 22
  givenname: Louis
  surname: Garrot
  fullname: Garrot, Louis
– sequence: 23
  givenname: Ronald
  surname: Kubica
  fullname: Kubica, Ronald
– sequence: 24
  givenname: Pranshu
  surname: Bansal
  fullname: Bansal, Pranshu
– sequence: 25
  givenname: Carrie
  surname: Marquette
  fullname: Marquette, Carrie
– sequence: 26
  givenname: Oscar
  surname: Goodman, Jr
  fullname: Goodman, Jr, Oscar
– sequence: 27
  givenname: Musharraf
  surname: Navaid
  fullname: Navaid, Musharraf
– sequence: 28
  givenname: Vijay
  surname: Chaudhary
  fullname: Chaudhary, Vijay
– sequence: 29
  givenname: April
  surname: Rose
  fullname: Rose, April
– sequence: 30
  givenname: Sebastien
  surname: Hotte
  fullname: Hotte, Sebastien
– sequence: 31
  givenname: Naveen
  surname: Basappa
  fullname: Basappa, Naveen
– sequence: 32
  givenname: Nimira
  surname: Alimohamed
  fullname: Alimohamed, Nimira
– sequence: 33
  givenname: Srikala
  surname: Sridhar
  fullname: Sridhar, Srikala
– sequence: 34
  givenname: Bernhard
  surname: Eigl
  fullname: Eigl, Bernhard
– sequence: 35
  givenname: Vincent
  surname: Castonguay
  fullname: Castonguay, Vincent
– sequence: 36
  givenname: Ricardo
  surname: Fernandes
  fullname: Fernandes, Ricardo
– sequence: 37
  givenname: Zineb
  surname: Hamilou
  fullname: Hamilou, Zineb
– sequence: 38
  givenname: Pawel
  surname: Zalewski
  fullname: Zalewski, Pawel
– sequence: 39
  givenname: Susanna
  surname: Cheng
  fullname: Cheng, Susanna
– sequence: 40
  givenname: Johannes
  surname: Voortman
  fullname: Voortman, Johannes
– sequence: 41
  givenname: Michiel
  surname: van der Heijden
  fullname: van der Heijden, Michiel
– sequence: 42
  givenname: Ronald
  surname: de Wit
  fullname: de Wit, Ronald
– sequence: 43
  givenname: Maartje
  surname: Los
  fullname: Los, Maartje
– sequence: 44
  givenname: Franchette
  surname: Van den Berkmortel
  fullname: Van den Berkmortel, Franchette
– sequence: 45
  givenname: Britt
  surname: Suelmann
  fullname: Suelmann, Britt
– sequence: 46
  givenname: Marco
  surname: Polee
  fullname: Polee, Marco
– sequence: 47
  givenname: Brieuc
  surname: Sautois
  fullname: Sautois, Brieuc
– sequence: 48
  givenname: Christof
  surname: Vulsteke
  fullname: Vulsteke, Christof
– sequence: 49
  givenname: Jean-Pascal
  surname: Machiels
  fullname: Machiels, Jean-Pascal
– sequence: 50
  givenname: Filip
  surname: Van Aelst
  fullname: Van Aelst, Filip
– sequence: 51
  givenname: Marlies
  surname: De Bock
  fullname: De Bock, Marlies
– sequence: 52
  givenname: Herlinde
  surname: Dumez
  fullname: Dumez, Herlinde
– sequence: 53
  givenname: Yohann
  surname: Loriot
  fullname: Loriot, Yohann
– sequence: 54
  givenname: Aude
  surname: Flechon
  fullname: Flechon, Aude
– sequence: 55
  givenname: Claude
  surname: Linassier
  fullname: Linassier, Claude
– sequence: 56
  givenname: Sophie
  surname: Tartas
  fullname: Tartas, Sophie
– sequence: 57
  givenname: Jose Pablo
  surname: Maroto Rey
  fullname: Maroto Rey, Jose Pablo
– sequence: 58
  givenname: Javier
  surname: Molina Cerrillo
  fullname: Molina Cerrillo, Javier
– sequence: 59
  givenname: Teresa
  surname: Alonso Gordoa
  fullname: Alonso Gordoa, Teresa
– sequence: 60
  givenname: Javier
  surname: Puente Vazquez
  fullname: Puente Vazquez, Javier
– sequence: 61
  givenname: Montserrat
  surname: Domenech
  fullname: Domenech, Montserrat
– sequence: 62
  givenname: Oscar
  surname: Reig Torras
  fullname: Reig Torras, Oscar
– sequence: 63
  givenname: Begoña
  surname: Mellado
  fullname: Mellado, Begoña
– sequence: 64
  givenname: Begona
  surname: Perez Valderrama
  fullname: Perez Valderrama, Begona
– sequence: 65
  givenname: Alberto
  surname: Font Pous
  fullname: Font Pous, Alberto
– sequence: 66
  givenname: Rafael
  surname: Morales Barrera
  fullname: Morales Barrera, Rafael
– sequence: 67
  givenname: Ignacio
  surname: Duran Martinez
  fullname: Duran Martinez, Ignacio
– sequence: 68
  givenname: Maria Jose
  surname: Mendez Vidal
  fullname: Mendez Vidal, Maria Jose
– sequence: 69
  givenname: Daniel
  surname: Castellano Gauna
  fullname: Castellano Gauna, Daniel
– sequence: 70
  givenname: Enrique
  surname: Gallardo Diaz
  fullname: Gallardo Diaz, Enrique
– sequence: 71
  givenname: Teresa
  surname: Bonfill
  fullname: Bonfill, Teresa
– sequence: 72
  givenname: Alejo
  surname: Rodriguez Vida
  fullname: Rodriguez Vida, Alejo
– sequence: 73
  givenname: Maria Jose
  surname: Juan Fita
  fullname: Juan Fita, Maria Jose
– sequence: 74
  givenname: Jose
  surname: Perez Gracia
  fullname: Perez Gracia, Jose
– sequence: 75
  givenname: Sergio
  surname: Vazquez Estevez
  fullname: Vazquez Estevez, Sergio
– sequence: 76
  givenname: Lajos
  surname: Geczi
  fullname: Geczi, Lajos
– sequence: 77
  givenname: Peter
  surname: Nyirady
  fullname: Nyirady, Peter
– sequence: 78
  givenname: Tibor
  surname: Csoszi
  fullname: Csoszi, Tibor
– sequence: 79
  givenname: Peter
  surname: Arkosy
  fullname: Arkosy, Peter
– sequence: 80
  givenname: Roberto
  surname: Iacovelli
  fullname: Iacovelli, Roberto
– sequence: 81
  givenname: Sergio
  surname: Bracarda
  fullname: Bracarda, Sergio
– sequence: 82
  givenname: Ugo
  surname: De Giorgi
  fullname: De Giorgi, Ugo
– sequence: 83
  givenname: Luca
  surname: Galli
  fullname: Galli, Luca
– sequence: 84
  givenname: Alketa
  surname: Hamzaj
  fullname: Hamzaj, Alketa
– sequence: 85
  givenname: Sabrina
  surname: Del Buono
  fullname: Del Buono, Sabrina
– sequence: 86
  givenname: Giuseppe
  surname: Fornarini
  fullname: Fornarini, Giuseppe
– sequence: 87
  givenname: Franco
  surname: Nole
  fullname: Nole, Franco
– sequence: 88
  givenname: Rodolfo
  surname: Passalacqua
  fullname: Passalacqua, Rodolfo
– sequence: 89
  givenname: Maddalena
  surname: Donini
  fullname: Donini, Maddalena
– sequence: 90
  givenname: Rossana
  surname: Berardi
  fullname: Berardi, Rossana
– sequence: 91
  givenname: Andrea
  surname: Necchi
  fullname: Necchi, Andrea
– sequence: 92
  givenname: Richard
  surname: Cathomas
  fullname: Cathomas, Richard
– sequence: 93
  givenname: Berna
  surname: Oezdemir
  fullname: Oezdemir, Berna
– sequence: 94
  givenname: Miklos
  surname: Pless
  fullname: Pless, Miklos
– sequence: 95
  givenname: Jindrich
  surname: Kopecky
  fullname: Kopecky, Jindrich
– sequence: 96
  givenname: Bohuslav
  surname: Melichar
  fullname: Melichar, Bohuslav
– sequence: 97
  givenname: Tomas
  surname: Buchler
  fullname: Buchler, Tomas
– sequence: 98
  givenname: Jana
  surname: Katolicka
  fullname: Katolicka, Jana
– sequence: 99
  givenname: Thomas
  surname: Powles
  fullname: Powles, Thomas
– sequence: 100
  givenname: Alison
  surname: Birtle
  fullname: Birtle, Alison
Copyright Copyright © 2024 Massachusetts Medical Society. All rights reserved.
Copyright © 2024 Massachusetts Medical Society.
Copyright_xml – notice: Copyright © 2024 Massachusetts Medical Society. All rights reserved.
– notice: Copyright © 2024 Massachusetts Medical Society.
CorporateAuthor EV-302 Trial Investigators
CorporateAuthor_xml – name: EV-302 Trial Investigators
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7RV
7X7
7XB
8AO
8C1
8FE
8FH
8FI
ABUWG
AFKRA
AN0
AZQEC
BBNVY
BEC
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
HCIFZ
K0Y
LK8
M0R
M0T
M1P
M2M
M2O
M2P
M7P
MBDVC
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PSYQQ
Q9U
7X8
DOI 10.1056/NEJMoa2312117
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Nursing & Allied Health Database
Health & Medical Collection (Proquest)
ProQuest Central (purchase pre-March 2016)
ProQuest Pharma Collection
Public Health Database
ProQuest SciTech Collection
ProQuest Natural Science Journals
ProQuest Hospital Collection
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
British Nursing Database (Proquest)
ProQuest Central Essentials
Biological Science Database
eLibrary
Download PDF from ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
SciTech Premium Collection
New England Journal of Medicine
Biological Sciences
Consumer Health Database
Health Management Database (Proquest)
Medical Database
ProQuest Psychology Database
ProQuest Research Library
Science Database
ProQuest Biological Science Database (NC LIVE)
Research Library (Corporate)
ProQuest Nursing and Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest One Psychology
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Psychology
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
elibrary
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
New England Journal of Medicine
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Public Health
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest Family Health
ProQuest One Academic Eastern Edition
British Nursing Index with Full Text
ProQuest Health Management
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList
ProQuest One Psychology
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1533-4406
EndPage 888
ExternalDocumentID 38446675
10_1056_NEJMoa2312117
NJ202403073901005
Genre Original Article
Clinical Trial, Phase III
Multicenter Study
Comparative Study
Randomized Controlled Trial
Journal Article
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GrantInformation Seagen
Merck
Astellas Pharma
GroupedDBID ---
-DZ
-ET
-~X
.-4
.55
.CO
.GJ
0R~
0WA
123
1VV
2KS
2WC
34G
36B
39C
4.4
5RE
7FN
7RV
7X7
85S
8C1
9M8
AACLI
AAEJM
AAIKC
AAMNW
AAQQT
AARDX
AAUTI
AAWTL
ABACO
ABCQX
ABEHJ
ABIVO
ABMYL
ABOCM
ABPPZ
ABQIJ
ABWJO
ACGFS
ACGOD
ACKOT
ACNCT
ACPFK
ACPRK
ACPVT
ACRZS
ADBBV
AENEX
AETEA
AFFNX
AFHKK
AFOSN
AGFXO
AGHSJ
AGNAY
AHMBA
AJJEV
ALMA_UNASSIGNED_HOLDINGS
BBNVY
BENPR
BHPHI
C45
CJ0
CS3
DCD
DU5
EBS
EX3
F5P
FD8
FM.
FYUFA
HCIFZ
HF~
HZ~
I4R
K-O
KOO
L7B
M0R
M0T
M1P
M2M
M2O
M2P
M7P
MQT
MVM
N4W
NEJ
O9-
OK1
OMK
OVD
P-O
P2P
RHI
RWL
RXW
S10
SJN
TAE
TAF
TEORI
TN5
TWZ
UCV
UKR
UMD
VQA
W2G
WH7
WOQ
WOW
X7M
XJT
XYN
XZL
YCJ
YFH
YR2
YRY
YYP
YZZ
ZA5
ZCA
ZR0
ZVN
~KM
29N
53G
8AO
8FE
8FH
8FI
AAYXX
ABBLC
ABDQB
ABJNI
ABUWG
ADUKH
AERZD
AFKRA
ALIPV
AN0
AQUVI
AZQEC
BCU
BKEYQ
BKNYI
BNQBC
BPHCQ
BVXVI
BYPQX
CCPQU
CITATION
DWQXO
GNUQQ
GUQSH
HMCUK
LK8
NAPCQ
PCD
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PSYQQ
SJFOW
TUQ
UKHRP
YR5
CGR
CUY
CVF
ECM
EIF
NPM
7XB
BEC
K0Y
MBDVC
PKEHL
PQEST
PQUKI
Q9U
7X8
ID FETCH-LOGICAL-c351t-a10a6af9d37b9c822aeafd09636bf03dd4b243e9c83dafdaf1623fb9d1e420693
IEDL.DBID 7X7
ISSN 0028-4793
1533-4406
IngestDate Fri Jul 11 12:34:01 EDT 2025
Sat Aug 23 14:44:43 EDT 2025
Mon Jul 21 05:19:31 EDT 2025
Thu Apr 24 23:07:07 EDT 2025
Thu Aug 07 05:28:14 EDT 2025
Sun Mar 10 16:40:47 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
License http://www.nejmgroup.org/legal/terms-of-use.htm
Copyright © 2024 Massachusetts Medical Society.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c351t-a10a6af9d37b9c822aeafd09636bf03dd4b243e9c83dafdaf1623fb9d1e420693
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ORCID 0000-0002-4607-5660
PMID 38446675
PQID 2938519198
PQPubID 40644
PageCount 14
ParticipantIDs proquest_miscellaneous_2942187710
proquest_journals_2938519198
pubmed_primary_38446675
crossref_citationtrail_10_1056_NEJMoa2312117
crossref_primary_10_1056_NEJMoa2312117
mms_nejm_10_1056_NEJMoa2312117
PublicationCentury 2000
PublicationDate 20240307
2024-03-07
PublicationDateYYYYMMDD 2024-03-07
PublicationDate_xml – month: 03
  year: 2024
  text: 20240307
  day: 07
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Boston
PublicationTitle The New England journal of medicine
PublicationTitleAlternate N Engl J Med
PublicationYear 2024
Publisher Massachusetts Medical Society
Publisher_xml – name: Massachusetts Medical Society
References (e_1_3_5_2_2) 2023
e_1_3_5_17_2
e_1_3_5_16_2
e_1_3_5_15_2
e_1_3_5_14_2
e_1_3_5_12_2
e_1_3_5_10_2
e_1_3_5_11_2
e_1_3_5_19_2
e_1_3_5_18_2
e_1_3_5_8_2
e_1_3_5_20_2
e_1_3_5_7_2
e_1_3_5_9_2
Olson D (e_1_3_5_13_2) 2022; 10
e_1_3_5_4_2
e_1_3_5_3_2
e_1_3_5_6_2
e_1_3_5_5_2
Morgans A (e_1_3_5_21_2) 2023; 29
References_xml – ident: e_1_3_5_7_2
  doi: 10.1016/S0140-6736(20)30230-0
– ident: e_1_3_5_17_2
  doi: 10.1016/j.urolonc.2023.03.012
– ident: e_1_3_5_20_2
  doi: 10.1200/JCO.2023.41.6_suppl.483
– ident: e_1_3_5_6_2
  doi: 10.1056/NEJMoa2309863
– ident: e_1_3_5_18_2
  doi: 10.1200/JCO.2023.41.6_suppl.466
– ident: e_1_3_5_16_2
  doi: 10.1016/S1470-2045(20)30541-6
– ident: e_1_3_5_12_2
  doi: 10.1016/S1470-2045(21)00094-2
– ident: e_1_3_5_15_2
  doi: 10.1200/JCO.22.01643
– ident: e_1_3_5_4_2
  doi: 10.1016/j.annonc.2021.11.012
– volume-title: SEER cancer stat facts: bladder cancer
  year: 2023
  ident: e_1_3_5_2_2
– ident: e_1_3_5_3_2
  doi: 10.1056/NEJMoa2002788
– ident: e_1_3_5_10_2
  doi: 10.1056/NEJMoa2035807
– ident: e_1_3_5_5_2
  doi: 10.2147/CLEP.S409791
– ident: e_1_3_5_14_2
  doi: 10.1200/JCO.22.02887
– ident: e_1_3_5_8_2
  doi: 10.1016/S1470-2045(21)00152-2
– volume: 29
  start-page: S20
  year: 2023
  ident: e_1_3_5_21_2
  article-title: Real-world avelumab maintenance eligibility and treatment patterns in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
  publication-title: J Manag Care Spec Pharm
– ident: e_1_3_5_19_2
  doi: 10.1200/JCO.2023.41.6_suppl.572
– ident: e_1_3_5_9_2
  doi: 10.1200/JCO.2021.39.15_suppl.4508
– ident: e_1_3_5_11_2
  doi: 10.1200/JCO.19.01140
– volume: 10
  start-page: A1231
  year: 2022
  ident: e_1_3_5_13_2
  article-title: Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors.
  publication-title: J Immunother Cancer
SSID ssj0000149
Score 2.7436335
Snippet In a trial comparing enfortumab vedotin and a PD-1 inhibitor with chemotherapy in patients with untreated advanced or metastatic urothelial cancer,...
No treatment has surpassed platinum-based chemotherapy in improving overall survival in patients with previously untreated locally advanced or metastatic...
AbstractBackgroundNo treatment has surpassed platinum-based chemotherapy in improving overall survival in patients with previously untreated locally advanced...
SourceID proquest
pubmed
crossref
mms
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 875
SubjectTerms Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Bladder cancer
Body weight
Cancer
Carboplatin
Carboplatin - administration & dosage
Carboplatin - adverse effects
Carboplatin - therapeutic use
Carcinoma, Transitional Cell - drug therapy
Carcinoma, Transitional Cell - pathology
Carcinoma, Transitional Cell - secondary
Chemotherapy
Cisplatin
Cisplatin - administration & dosage
Cisplatin - adverse effects
Cisplatin - therapeutic use
Clinical outcomes
Drug dosages
Gemcitabine
Gemcitabine - administration & dosage
Gemcitabine - adverse effects
Gemcitabine - therapeutic use
Genitourinary Cancer
Hematology
Humans
Immunotherapy
Metastases
Metastasis
Monoclonal antibodies
Oncology
Patients
Pembrolizumab
Platinum
Prostate Disease
Prostate Disease General
Safety
Survival
Survival Analysis
Targeted cancer therapy
Treatments in Oncology
Urinary Bladder Neoplasms
Urologic Neoplasms - drug therapy
Urologic Neoplasms - pathology
Urologic Neoplasms - secondary
Urology
Urothelial cancer
Urothelial carcinoma
SubjectTermsDisplay Genitourinary Cancer
Hematology/Oncology
Treatments in Oncology
Urology/Prostate Disease
Urology/Prostate Disease General
Title Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
URI https://nejm.org/doi/full/10.1056/NEJMoa2312117
https://www.ncbi.nlm.nih.gov/pubmed/38446675
https://www.proquest.com/docview/2938519198
https://www.proquest.com/docview/2942187710
Volume 390
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEB6sgngR39ZHiSCeDE2ym6R7Ei0VEZUiVnoLu9ldUEyqfVz89c6k22oP9ZJDZghhX_PNfLMzAOcthnaGW-MTZeZzK1q-4kb6Eq2rjQTVZKOA_uNTctfj9_247wJuI5dWOTsTq4NaD3KKkTfRLCE4EOgjX31--dQ1ithV10KjBmtUuoxSutJ--qd8lIO_LoLkamyizW9Sp_mBRHCDDlC6YJNqRTFaDjcrs3O7BZsOL3rX0wnehhVT7sD6o2PEd-GhQ_eJxpNCKu_VoIv5Vnqy1F7XFIoa8nxXEnzZK6uccqO9a0f7e70hXb_6wBXotenNcA96t52X9p3vOiT4OYvDsS_DQCbSCs1SJXK09dJIq9ErYYmyAdOaq4gzgyKmUSBtiGjHKqFDw6MgEWwfVstBaQ7BM9bKWOiAstZ4zriwKsgTLfOIyncnQR0uZ2OU5a58OHWx-MgqGjtOsoUhrcPFXP1zWjdjmWIDBzwrzXuxTOFkNheZ21-j7Hc11OFsLsadQXSHLM1gQjoc8UuKEKoOB9M5nP8KaxGPncZH_3_8GDYiBDFVzll6Aqvj4cScIggZq0a10vDZaocNWLvpPHWffwAPodml
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-VVhq8oMH4KIxipMET0dLYSZqHCZXSqWNtNaEV7S2zY1sCLenohxD8Ufsbd5c6HX0ob3v1naLofPb9zvcFcNDhaGeENR6FzDxhk46nhJGeROtqg4R6stGD_mgcDSbi60V4UYObqhaG0iqrO7G8qPU0ozfyQzRLCA4S9JE_Xf_yaGoURVerERortTg1f36jyzY_OvmC-_s-CI77572B56YKeBkP2wtPtn0ZSZtoHqskQ_sojbQakTyPlPW51kIFghskcY0EaduIEKxKdNuIwI-o-RJe-Q3B0ZWpQ-Nzf3z27Z-GVQ5wuzcr19UTUcYhzbafSoRT6HLFG1bwQZ7PtwPc0tAd78Jjh1BZd6VST6BmiqewM3Ix-D0Y9qmCabHMpWLfDTq1PwomC83OTK5oBNDfkoKLk6LMYjeadV2iAZvMqODrCnWe9Whl9gwm9yK951AvpoV5CcxYK8NE-5QnJzIuEqv8LNIyC6hheOQ34WMlozRzDctpbsZVWgbOwyjdEGkTPqzZr1edOrYxtlDgaWF-5tsY9qu9SN2Jnqd3-teEd2synkUKsMjCTJfEIxAxxQjamvBitYfrX-EdipzH4av_f_wtPBycj4bp8GR8-hoeBQihyoy3eB_qi9nSvEEItFAtp3cMLu9b1W8Bok4XFg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT-QwDLZYkNBeELDADs-sBHuimk6TttMDQggY8RYHZjW3kjSJtIh2YB5C8NP4ddiddIDDcOMaW1HkOPHn2LEBtpsc7YywxqOQmSds0vSUMNKTaF1tkFBNNnrQv7yKTtrirBN2puC1-gtDaZXVnVhe1Lqb0Rt5Hc0SgoMEfeS6dWkR10et_YdHjzpIUaS1aqcxUpFz8_yE7lt_7_QI93onCFrHN4cnnusw4GU8bAw82fBlJG2ieaySDG2lNNJqRPU8UtbnWgsVCG6QxDUSpG0gWrAq0Q0jAj-iQkx4_c_EOBmdsbgTfyhd5aC3e71y9T0Rb9Spy31XIrBC5yv-ZA9_5Hl_MtQtTV5rHuYcVmUHI-VagClTLMLspYvG_4KLY_rLNBjmUrF_Bt3b_wWThWbXJlfUDOilpOBguyjz2Y1mBy7lgLV79PXrHrWfHdJIbwna3yK7ZZguuoX5DcxYK8NE-5QxJzIuEqv8LNIyC6h0eOTXYLeSUZq50uXUQeM-LUPoYZR-EmkN_o7ZH0Y1OyYxbqLA08Lc5ZMY1qu9SN3Z7qfvmliDP2MynkoKtcjCdIfEIxA7xQjfarAy2sPxUniTYuhxuPr15FswiwqeXpxena_BzwCxVJn6Fq_D9KA3NBuIhQZqs1Q6BrffreVvsdMZ5g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Enfortumab+Vedotin+and+Pembrolizumab+in+Untreated+Advanced+Urothelial+Cancer&rft.jtitle=The+New+England+journal+of+medicine&rft.au=Powles%2C+Thomas&rft.au=Valderrama%2C+Bego%C3%B1a+P&rft.au=Gupta%2C+Shilpa&rft.au=Bedke%2C+Jens&rft.date=2024-03-07&rft.pub=Massachusetts+Medical+Society&rft.issn=0028-4793&rft.eissn=1533-4406&rft.volume=390&rft.issue=10&rft.spage=875&rft.epage=888&rft_id=info:doi/10.1056%2FNEJMoa2312117&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon